Overview

Lopinavir/Ritonavir in PLWH With High-Grade AIN

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on study for up to 40 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Wisconsin Partnership Program

Treatments:

Lopinavir
Ritonavir